EZH2 and epithelioid sarcoma: While limited in patient number, these two studies would suggest that unless the epigenetic target plays a role as an oncogenic driver, as in epithelioid sarcoma and EZH2 gain of function mutation, future efforts should focus on combination therapies with known cytotoxic agents as opposed to epigenetic targets as monotherapies[62].